[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.159.27. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
December 2014

Dopamine Receptor Agonist Drugs and Impulse Control Disorders

Author Affiliations
  • 1Sinai Hospital of Baltimore, Baltimore, Maryland
  • 2Department of Neurology and Neurological Sciences, Johns Hopkins University, Baltimore, Maryland
  • 3Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
JAMA Intern Med. 2014;174(12):1935-1937. doi:10.1001/jamainternmed.2014.4097

The discovery of striatal dopamine deficiency and the introduction of levodopa in the 1960s as treatment for the motor symptoms of Parkinson disease revolutionized neurology and neurotherapeutics. For the first time, patients with an apparently hopeless chronic degenerative brain disorder were able to regain function and return to the mainstream of life. Levodopa was subsequently combined with carbidopa, as the latter prevented the adverse effects associated with peripheral dopamine synthesis without blocking central dopamine synthesis.

First Page Preview View Large
First page PDF preview
First page PDF preview
×